New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2014
08:15 EDTRDHLRedHill Biopharma, IntelGenx submit response to FDA CRL for VersaFilm product
IntelGenx announced, together with RedHill Biopharma that they submitted a response to the Complete Response Letter of the U.S. Food and Drug Administration for the New Drug Application for their VersaFilm Oral Film Product for the treatment of acute migraines.The companies previously reported on February 4 that they received the FDA's CRL which raised questions primarily related to third party Chemistry, Manufacturing and Controls (CMC) and to the packaging and labeling of the product. The FDA's CRL did not raise any questions or deficiencies relating to the anti-migraine VersaFilm product's safety and did not require additional clinical studies. IntelGenx and RedHill believe that their response to the FDA addresses all the issues raised in the CRL. IntelGenx and RedHill will continue working with the FDA on the continuing review of the anti-migraine VersaFilm NDA, and will provide additional updates as and when applicable.
News For RDHL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
07:17 EDTRDHLRedHill Biopharma awarded additional U.S. patent for RHB-105
RedHill Biopharma announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent No. 14/179,197 covering the RHB-105 formulation. RHB-105 is a proprietary fixed-dose combination therapy of two antibiotics and a proton pump inhibitor, or PPI, in an all-in-one oral capsule, targeting an indication of first line treatment of Helicobacter pylori, or H. pylori, infection. The new RHB-105 patent application is entitled "Pharmaceutical Compositions for the Treatment of Helicobacter Pylori". Once granted, the patent is expected to be valid until at least 2034.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use